Citigroup Maintains Buy on Beam Therapeutics, Lowers Price Target to $56
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Samantha Semenkow has maintained a 'Buy' rating on Beam Therapeutics (NASDAQ:BEAM) but lowered the price target from $60 to $56.
August 09, 2023 | 11:42 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Citigroup has maintained a 'Buy' rating on Beam Therapeutics but lowered the price target from $60 to $56.
The news is directly related to Beam Therapeutics. While the 'Buy' rating is maintained, the lowering of the price target might create some uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100